DELAWARE | 1-11083 | 04-2695240 |
(State or other | (Commission | (IRS employer |
jurisdiction of | file number) | identification no.) |
incorporation) |
One Boston Scientific Place, Natick, Massachusetts | 01760-1537 |
(Address of principal executive offices) | (Zip code) |
o | Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
o | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
o | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
o | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Date: October 18, 2012 | BOSTON SCIENTIFIC CORPORATION | ||
By: | /s/ Vance R. Brown | ||
Vance R. Brown | |||
Vice President and Chief Corporate Counsel | |||
Exhibit No. | Description |
99.1 | Press Release issued by Boston Scientific Corporation dated October 18, 2012 |
• | Reported sales of $1.735 billion, a decline of 7 percent on a reported basis and 5 percent on a constant currency basis excluding divested businesses, at the lower end of the company's guidance. |
• | Delivered adjusted EPS of $0.16, at the higher end of the company's adjusted EPS guidance range of $0.14 to $0.17. |
• | Generated strong operating cash flow of $271 million. |
• | Repurchased approximately 46 million shares under the 2011 share repurchase authorization, bringing the total shares repurchased to 169 million shares, or 11 percent of shares outstanding, during the past 18 months. |
• | The company received two significant regulatory approvals: |
◦ | Early U.S. Food and Drug Administration regulatory approval of the S-ICD® System, the world's first and only commercially available subcutaneous implantable defibrillator. |
◦ | CE Mark approval of the Vercise™ Deep Brain Stimulation (DBS) System for the treatment of Parkinson's disease, entering a new therapeutic category. |
• | The company made two strategic acquisitions: |
◦ | BridgePoint Medical, Inc., which develops a proprietary, catheter-based system to treat coronary chronic total occlusions. |
◦ | Rhythmia Medical, Inc., which develops a next-generation mapping and navigation solutions for use in electrophysiology procedures. |
Change | ||||||||||||||||||
Three Months Ended | As Reported | Constant | ||||||||||||||||
September 30, | Currency | Currency | ||||||||||||||||
in millions | 2012 | 2011 | Basis | Basis | ||||||||||||||
Interventional Cardiology | $ | 494 | $ | 613 | (20 | ) | % | (17 | ) | % | ||||||||
Cardiac Rhythm Management | 462 | 503 | (8 | ) | % | (6 | ) | % | ||||||||||
Endoscopy | 310 | 298 | 4 | % | 7 | % | ||||||||||||
Peripheral Interventions | 189 | 182 | 4 | % | 7 | % | ||||||||||||
Urology/Women's Health | 125 | 124 | — | % | 1 | % | ||||||||||||
Neuromodulation | 88 | 84 | 5 | % | 5 | % | ||||||||||||
Electrophysiology | 35 | 36 | (2 | ) | % | — | % | |||||||||||
Subtotal Core Businesses | 1,703 | 1,840 | (7 | ) | % | (5 | ) | % | ||||||||||
Divested Businesses | 32 | 34 | N/A | N/A | ||||||||||||||
Worldwide | $ | 1,735 | $ | 1,874 | (7 | ) | % | (5 | ) | % | ||||||||
CONTACT: | Steven Campanini |
508-652-5740 (office) | |
Media Relations | |
Boston Scientific Corporation | |
steven.campanini@bsci.com |
Denise Kaigler | |
508-650-8330 (office) | |
Media Relations | |
Boston Scientific Corporation | |
denise.kaigler@bsci.com |
Michael Campbell | |
508-650-8023 (office) | |
Investor Relations | |
Boston Scientific Corporation | |
investor_relations@bsci.com |
Three Months Ended | Nine Months Ended | |||||||||||||
September 30, | September 30, | |||||||||||||
in millions, except per share data | 2012 | 2011 | 2012 | 2011 | ||||||||||
Net sales | $ | 1,735 | $ | 1,874 | $ | 5,428 | $ | 5,774 | ||||||
Cost of products sold | 558 | 680 | 1,767 | 1,999 | ||||||||||
Gross profit | 1,177 | 1,194 | 3,661 | 3,775 | ||||||||||
Operating expenses: | ||||||||||||||
Selling, general and administrative expenses | 589 | 629 | 1,895 | 1,866 | ||||||||||
Research and development expenses | 220 | 229 | 648 | 665 | ||||||||||
Royalty expense | 29 | 36 | 125 | 140 | ||||||||||
Amortization expense | 99 | 97 | 294 | 325 | ||||||||||
Goodwill impairment charges | 809 | 4,411 | 697 | |||||||||||
Intangible asset impairment charges | 13 | 9 | 142 | 21 | ||||||||||
Contingent consideration expense (benefit) | (20 | ) | 6 | (9 | ) | 18 | ||||||||
Restructuring charges | 54 | 22 | 93 | 77 | ||||||||||
Litigation-related charges | 50 | 119 | ||||||||||||
Gain on divestiture | (11 | ) | (8 | ) | (11 | ) | (768 | ) | ||||||
1,832 | 1,020 | 7,707 | 3,041 | |||||||||||
Operating (loss) income | (655 | ) | 174 | (4,046 | ) | 734 | ||||||||
Other (expense) income: | ||||||||||||||
Interest expense | (65 | ) | (62 | ) | (197 | ) | (210 | ) | ||||||
Other, net | (4 | ) | (1 | ) | 23 | 18 | ||||||||
(Loss) income before income taxes | (724 | ) | 111 | (4,220 | ) | 542 | ||||||||
Income tax (benefit) expense | 1 | (31 | ) | (30 | ) | 208 | ||||||||
Net (loss) income | $ | (725 | ) | $ | 142 | $ | (4,190 | ) | $ | 334 | ||||
Net (loss) income per common share - basic | $ | (0.52 | ) | $ | 0.09 | $ | (2.95 | ) | $ | 0.22 | ||||
Net (loss) income per common share - assuming dilution | $ | (0.52 | ) | $ | 0.09 | $ | (2.95 | ) | $ | 0.22 | ||||
Weighted-average shares outstanding | ||||||||||||||
Basic | 1,392.5 | 1,514.4 | 1,420.3 | 1,523.1 | ||||||||||
Assuming dilution | 1,392.5 | 1,524.0 | 1,420.3 | 1,532.0 |
As of | |||||||||
September 30, | December 31, | ||||||||
in millions, except share and per share data | 2012 | 2011 | |||||||
(Unaudited) | |||||||||
ASSETS | |||||||||
Current assets: | |||||||||
Cash and cash equivalents | $ | 352 | $ | 267 | |||||
Trade accounts receivable, net | 1,197 | 1,246 | |||||||
Inventories | 911 | 931 | |||||||
Deferred income taxes | 483 | 458 | |||||||
Prepaid expenses and other current assets | 230 | 203 | |||||||
Total current assets | 3,173 | 3,105 | |||||||
Property, plant and equipment, net | 1,624 | 1,670 | |||||||
Goodwill | 5,663 | 9,761 | |||||||
Other intangible assets, net | 6,154 | 6,473 | |||||||
Other long-term assets | 223 | 281 | |||||||
$ | 16,837 | $ | 21,290 | ||||||
LIABILITIES AND STOCKHOLDERS' EQUITY | |||||||||
Current liabilities: | |||||||||
Current debt obligations | $ | 3 | $ | 4 | |||||
Accounts payable | 228 | 203 | |||||||
Accrued expenses | 1,325 | 1,327 | |||||||
Other current liabilities | 204 | 273 | |||||||
Total current liabilities | 1,760 | 1,807 | |||||||
Long-term debt | 4,252 | 4,257 | |||||||
Deferred income taxes | 1,760 | 1,865 | |||||||
Other long-term liabilities | 2,298 | 2,008 | |||||||
Commitments and contingencies | |||||||||
Stockholders' equity | |||||||||
Preferred stock, $.01 par value - authorized 50,000,000 | |||||||||
shares, none issued and outstanding | |||||||||
Common stock, $.01 par value - authorized 2,000,000,000 | |||||||||
shares, issued 1,541,569,188 shares as of September 30, | |||||||||
2012 and 1,531,006,390 shares as of December 31, 2011 | 15 | 15 | |||||||
Treasury stock, at cost - 168,697,617 shares as of September 30, | |||||||||
2012 and 81,950,716 shares as of December 31, 2011 | (992 | ) | (492 | ) | |||||
Additional paid-in capital | 16,427 | 16,349 | |||||||
Accumulated deficit | (8,571 | ) | (4,381 | ) | |||||
Other stockholders' deficit | (112 | ) | (138 | ) | |||||
Total stockholders' equity | 6,767 | 11,353 | |||||||
$ | 16,837 | $ | 21,290 | ||||||
Three Months Ended September 30, | |||||||||||||||
2012 | 2011 | ||||||||||||||
Net | Impact | Impact | |||||||||||||
(loss) | per diluted | Net | per diluted | ||||||||||||
in millions, except per share data | income | share | income | share | |||||||||||
GAAP net (loss) income | $ | (725 | ) | $ | (0.52 | ) | $ | 142 | $ | 0.09 | |||||
Non-GAAP adjustments: | |||||||||||||||
Goodwill impairment charge | 809 | 0.58 | * | ||||||||||||
Intangible asset impairment charges | 10 | 0.01 | * | 7 | 0.01 | ||||||||||
Acquisition-related net (credits) charges | (20 | ) | (0.01 | ) | * | 7 | 0.01 | ||||||||
Divestiture-related net credits | (8 | ) | (0.01 | ) | * | (5 | ) | 0.00 | |||||||
Restructuring-related charges | 39 | 0.03 | * | 19 | 0.01 | ||||||||||
Litigation-related charges | 32 | 0.02 | * | ||||||||||||
Discrete tax items | 1 | — | * | (25 | ) | (0.02 | ) | ||||||||
Amortization expense | 83 | 0.06 | * | 78 | 0.05 | ||||||||||
Adjusted net income | $ | 221 | $ | 0.16 | $ | 223 | $ | 0.15 | |||||||
Nine Months Ended September 30, | |||||||||||||||
2012 | 2011 | ||||||||||||||
Net | Impact | Impact | |||||||||||||
(loss) | per diluted | Net | per diluted | ||||||||||||
in millions, except per share data | income | share | income | share | |||||||||||
GAAP net (loss) income | $ | (4,190 | ) | $ | (2.95 | ) | $ | 334 | $ | 0.22 | |||||
Non-GAAP adjustments: | |||||||||||||||
Goodwill impairment charges | 4,389 | 3.09 | * | 697 | 0.45 | ||||||||||
Intangible asset impairment charges | 119 | 0.09 | * | 16 | 0.01 | ||||||||||
Acquisition-related net credits | (30 | ) | (0.02 | ) | * | (17 | ) | (0.01 | ) | ||||||
Divestiture-related net credits | (5 | ) | — | * | (533 | ) | (0.35 | ) | |||||||
Restructuring-related charges | 76 | 0.05 | * | 75 | 0.05 | ||||||||||
Litigation-related charges | 72 | 0.05 | * | ||||||||||||
Discrete tax items | 1 | — | * | (21 | ) | (0.01 | ) | ||||||||
Amortization expense | 248 | 0.17 | * | 271 | 0.18 | ||||||||||
Adjusted net income | $ | 680 | $ | 0.48 | $ | 822 | $ | 0.54 | |||||||
Three Months Ended | Nine Months Ended | |||||||||||||
in millions | September 30, | September 30, | ||||||||||||
2012 | 2011 | 2012 | 2011 | |||||||||||
Goodwill impairment charges: | ||||||||||||||
Goodwill impairment charges | $ | 809 | $ | 4,411 | $ | 697 | ||||||||
Income tax benefit (a) | (22 | ) | ||||||||||||
Goodwill impairment charges, net of tax | $ | 809 | $ | 4,389 | $ | 697 | ||||||||
Intangible asset impairment charges: | ||||||||||||||
Intangible asset impairment charges | $ | 13 | $ | 9 | $ | 142 | $ | 21 | ||||||
Income tax benefit (a) | (3 | ) | (2 | ) | (23 | ) | (5 | ) | ||||||
Intangible asset impairment charges, net of tax | $ | 10 | $ | 7 | $ | 119 | $ | 16 | ||||||
Acquisition-related net (credits) charges: | ||||||||||||||
Contingent consideration (benefit) expense | $ | (20 | ) | $ | 6 | $ | (9 | ) | $ | 18 | ||||
Acquisition-related costs (b) | 1 | 7 | 3 | |||||||||||
Inventory step-up adjustment (c) | 1 | 2 | ||||||||||||
Gain on previously held investments (d) | (39 | ) | (38 | ) | ||||||||||
(20 | ) | 8 | (41 | ) | (15 | ) | ||||||||
Income tax (expense) benefit (a) | (1 | ) | 11 | (2 | ) | |||||||||
Acquisition-related net (credits) charges, net of tax | $ | (20 | ) | $ | 7 | $ | (30 | ) | $ | (17 | ) | |||
Divestiture-related net credits: | ||||||||||||||
Gain on divestiture | $ | (11 | ) | $ | (8 | ) | $ | (11 | ) | $ | (768 | ) | ||
Divestiture-related costs (c) | $ | 1 | $ | 1 | $ | 4 | 4 | |||||||
(10 | ) | (7 | ) | (7 | ) | (764 | ) | |||||||
Income tax expense (a) | 2 | 2 | 2 | 231 | ||||||||||
Divestiture-related net credits, net of tax | $ | (8 | ) | $ | (5 | ) | $ | (5 | ) | $ | (533 | ) | ||
Restructuring-related charges: | ||||||||||||||
Restructuring charges | $ | 54 | $ | 22 | $ | 93 | $ | 77 | ||||||
Restructuring-related charges (e) | 4 | 7 | 15 | 32 | ||||||||||
58 | 29 | 108 | 109 | |||||||||||
Income tax benefit (a) | (19 | ) | (10 | ) | (32 | ) | (34 | ) | ||||||
Restructuring-related charges, net of tax | $ | 39 | $ | 19 | $ | 76 | $ | 75 | ||||||
Litigation-related net charges: | ||||||||||||||
Litigation-related net charges | $ | 50 | $ | 119 | ||||||||||
Income tax benefit (a) | (18 | ) | (47 | ) | ||||||||||
Litigation-related net charges, net of tax | $ | 32 | $ | 72 | ||||||||||
Discrete tax items: | ||||||||||||||
Income tax expense (benefit) (a) | 1 | (25 | ) | $ | 1 | $ | (21 | ) | ||||||
Amortization expense: | ||||||||||||||
Amortization expense | $ | 99 | $ | 97 | $ | 294 | $ | 325 | ||||||
Income tax benefit (a) | (16 | ) | (19 | ) | (46 | ) | (54 | ) | ||||||
Amortization expense, net of tax | $ | 83 | $ | 78 | $ | 248 | $ | 271 |
(a) | Amounts are tax effected at the Company's effective tax rate, unless the amount is a significant unusual or infrequently occurring item in accordance with FASB Accounting Standards Codification section 740-270-30, "General Methodology and Use of Estimated Annual Effective Tax Rate." |
(b) | Recorded to selling, general and administrative expenses. |
(c) | Recorded to cost of products sold. |
(d) | Recorded to other, net. |
(e) | In the third quarter of 2012, recorded $1 million to cost of products sold and $3 million to selling, general and administrative expenses. In the third quarter of 2011, recorded $7 million to cost of products sold. In the first nine months of 2012, recorded $7 million to cost of products sold and $8 million to selling, general and administrative expenses. In the first nine months of 2011, recorded $28 million to cost of products sold and $4 million to selling, general and administrative expenses. |
Change | ||||||||||||||
Three Months Ended | As Reported | Constant | ||||||||||||
September 30, | Currency | Currency | ||||||||||||
in millions | 2012 | 2011 | Basis | Basis | ||||||||||
(restated) | * | |||||||||||||
United States | $ | 907 | $ | 990 | (8 | ) | % | (8 | ) | % | ||||
EMEA | 355 | 411 | (14 | ) | % | (5 | ) | % | ||||||
Japan | 222 | 235 | (6 | ) | % | (5 | ) | % | ||||||
Inter-Continental | 219 | 204 | 7 | % | 12 | % | ||||||||
International | 796 | 850 | (6 | ) | % | (1 | ) | % | ||||||
Subtotal Core Businesses | 1,703 | 1,840 | (7 | ) | % | (5 | ) | % | ||||||
Divested Businesses | 32 | 34 | N/A | N/A | ||||||||||
Worldwide | $ | 1,735 | $ | 1,874 | (7 | ) | % | (5 | ) | % | ||||
Change | ||||||||||||||
Three Months Ended | As Reported | Constant | ||||||||||||
September 30, | Currency | Currency | ||||||||||||
in millions | 2012 | 2011 | Basis | Basis | ||||||||||
Interventional Cardiology | $ | 494 | $ | 613 | (20 | ) | % | (17 | ) | % | ||||
Cardiac Rhythm Management | 462 | 503 | (8 | ) | % | (6 | ) | % | ||||||
Endoscopy | 310 | 298 | 4 | % | 7 | % | ||||||||
Peripheral Interventions | 189 | 182 | 4 | % | 7 | % | ||||||||
Urology/Women's Health | 125 | 124 | — | % | 1 | % | ||||||||
Neuromodulation | 88 | 84 | 5 | % | 5 | % | ||||||||
Electrophysiology | 35 | 36 | (2 | ) | % | — | % | |||||||
Subtotal Core Businesses | 1,703 | 1,840 | (7 | ) | % | (5 | ) | % | ||||||
Divested Businesses | 32 | 34 | N/A | N/A | ||||||||||
Worldwide | $ | 1,735 | $ | 1,874 | (7 | ) | % | (5 | ) | % | ||||
Change | ||||||||||||||
Nine Months Ended | As Reported | Constant | ||||||||||||
September 30, | Currency | Currency | ||||||||||||
in millions | 2012 | 2011 | Basis | Basis | ||||||||||
(restated) | * | |||||||||||||
United States | $ | 2,833 | $ | 3,054 | (7 | ) | % | (7 | ) | % | ||||
EMEA | 1,172 | 1,311 | (11 | ) | % | (3 | ) | % | ||||||
Japan | 695 | 705 | (1 | ) | % | (3 | ) | % | ||||||
Inter-Continental | 637 | 593 | 7 | % | 11 | % | ||||||||
International | 2,504 | 2,609 | (4 | ) | % | — | % | |||||||
Subtotal Core Businesses | 5,337 | 5,663 | (6 | ) | % | (4 | ) | % | ||||||
Divested Businesses | 91 | 111 | N/A | N/A | ||||||||||
Worldwide | $ | 5,428 | $ | 5,774 | (6 | ) | % | (4 | ) | % | ||||
Change | ||||||||||||||
Nine Months Ended | As Reported | Constant | ||||||||||||
September 30, | Currency | Currency | ||||||||||||
in millions | 2012 | 2011 | Basis | Basis | ||||||||||
Interventional Cardiology | $ | 1,646 | $ | 1,901 | (13 | ) | % | (11 | ) | % | ||||
Cardiac Rhythm Management | 1,451 | 1,606 | (10 | ) | % | (8 | ) | % | ||||||
Endoscopy | 922 | 883 | 4 | % | 6 | % | ||||||||
Peripheral Interventions | 575 | 547 | 5 | % | 7 | % | ||||||||
Urology/Women's Health | 371 | 371 | — | % | — | % | ||||||||
Neuromodulation | 263 | 245 | 7 | % | 8 | % | ||||||||
Electrophysiology | 109 | 110 | (1 | ) | % | — | % | |||||||
Subtotal Core Businesses | 5,337 | 5,663 | (6 | ) | % | (4 | ) | % | ||||||
Divested Businesses | 91 | 111 | N/A | N/A | ||||||||||
Worldwide | $ | 5,428 | $ | 5,774 | (6 | ) | % | (4 | ) | % | ||||
Q3 2012 Net Sales as compared to Q3 2011 | ||||||||||
Change | Estimated | |||||||||
As Reported | Constant | Impact of | ||||||||
Currency | Currency | Foreign | ||||||||
in millions | Basis | Basis | Currency | |||||||
United States | $ | (83 | ) | $ | (83 | ) | ||||
EMEA | (56 | ) | (20 | ) | $ | (36 | ) | |||
Japan | (13 | ) | (9 | ) | (4 | ) | ||||
Inter-Continental | 15 | 22 | (7 | ) | ||||||
International | (54 | ) | (7 | ) | (47 | ) | ||||
Subtotal Core Businesses | (137 | ) | (90 | ) | (47 | ) | ||||
Divested Businesses | (2 | ) | (2 | ) | — | |||||
Worldwide | $ | (139 | ) | $ | (92 | ) | $ | (47 | ) | |
Q3 2012 Net Sales as compared to Q3 2011 | ||||||||||
Change | Estimated | |||||||||
As Reported | Constant | Impact of | ||||||||
Currency | Currency | Foreign | ||||||||
in millions | Basis | Basis | Currency | |||||||
Interventional Cardiology | $ | (119 | ) | $ | (99 | ) | $ | (20 | ) | |
Cardiac Rhythm Management | (41 | ) | (29 | ) | (12 | ) | ||||
Endoscopy | 12 | 20 | (8 | ) | ||||||
Peripheral Interventions | 7 | 13 | (6 | ) | ||||||
Urology/Women's Health | 1 | 2 | (1 | ) | ||||||
Neuromodulation | 4 | 4 | ||||||||
Electrophysiology | (1 | ) | (1 | ) | ||||||
Subtotal Core Businesses | (137 | ) | (90 | ) | (47 | ) | ||||
Divested Businesses | (2 | ) | (2 | ) | ||||||
Worldwide | $ | (139 | ) | $ | (92 | ) | $ | (47 | ) | |
Q3 2012 YTD Net Sales as compared to Q3 2011 YTD | ||||||||||
Change | Estimated | |||||||||
As Reported | Constant | Impact of | ||||||||
Currency | Currency | Foreign | ||||||||
in millions | Basis | Basis | Currency | |||||||
United States | $ | (221 | ) | $ | (221 | ) | ||||
EMEA | (139 | ) | (44 | ) | $ | (95 | ) | |||
Japan | (10 | ) | (17 | ) | 7 | |||||
Inter-Continental | 44 | 60 | (16 | ) | ||||||
International | (105 | ) | (1 | ) | (104 | ) | ||||
Subtotal Core Businesses | (326 | ) | (222 | ) | (104 | ) | ||||
Divested Businesses | (20 | ) | (19 | ) | (1 | ) | ||||
Worldwide | $ | (346 | ) | $ | (241 | ) | $ | (105 | ) | |
Q3 2012 YTD Net Sales as compared to Q3 2011 YTD | ||||||||||
Change | Estimated | |||||||||
As Reported | Constant | Impact of | ||||||||
Currency | Currency | Foreign | ||||||||
in millions | Basis | Basis | Currency | |||||||
Interventional Cardiology | $ | (255 | ) | $ | (213 | ) | $ | (42 | ) | |
Cardiac Rhythm Management | (155 | ) | (124 | ) | (31 | ) | ||||
Endoscopy | 39 | 55 | (16 | ) | ||||||
Peripheral Interventions | 28 | 39 | (11 | ) | ||||||
Urology/Women's Health | 2 | (2 | ) | |||||||
Neuromodulation | 18 | 19 | (1 | ) | ||||||
Electrophysiology | (1 | ) | (1 | ) | ||||||
Subtotal Core Businesses | (326 | ) | (222 | ) | (104 | ) | ||||
Divested Businesses | (20 | ) | (19 | ) | (1 | ) | ||||
Worldwide | $ | (346 | ) | $ | (241 | ) | $ | (105 | ) | |
in millions | U.S. | International | Worldwide | ||||||||||||||||||
Q3 2012 | Q3 2011 | Q3 2012 | Q3 2011 | Q3 2012 | Q3 2011 | ||||||||||||||||
Defibrillator systems | $ | 205 | $ | 225 | $ | 122 | $ | 135 | $ | 327 | $ | 360 | |||||||||
Pacemaker systems | 68 | 71 | 67 | 72 | 135 | 143 | |||||||||||||||
Total CRM products | $ | 273 | $ | 296 | $ | 189 | $ | 207 | $ | 462 | $ | 503 |
in millions | U.S. | International | Worldwide | ||||||||||||||||||
Q3 2012 | Q3 2011 | Q3 2012 | Q3 2011 | Q3 2012 | Q3 2011 | ||||||||||||||||
Drug-eluting stent systems | $ | 123 | $ | 191 | $ | 160 | $ | 184 | $ | 283 | $ | 375 | |||||||||
Bare-metal stent systems | 6 | 7 | 15 | 20 | 21 | 27 | |||||||||||||||
Total coronary stent systems | $ | 129 | $ | 198 | $ | 175 | $ | 204 | $ | 304 | $ | 402 |
in millions | U.S. | International | Worldwide | ||||||||||||||||||
YTD 2012 | YTD 2011 | YTD 2012 | YTD 2011 | YTD 2012 | YTD 2011 | ||||||||||||||||
Defibrillator systems | $ | 655 | $ | 734 | $ | 395 | $ | 436 | $ | 1,050 | $ | 1,170 | |||||||||
Pacemaker systems | 194 | 216 | 207 | 220 | 401 | 436 | |||||||||||||||
Total CRM products | $ | 849 | $ | 950 | $ | 602 | $ | 656 | $ | 1,451 | $ | 1,606 |
in millions | U.S. | International | Worldwide | ||||||||||||||||||
YTD 2012 | YTD 2011 | YTD 2012 | YTD 2011 | YTD 2012 | YTD 2011 | ||||||||||||||||
Drug-eluting stent systems | $ | 439 | $ | 583 | $ | 525 | $ | 571 | $ | 964 | $ | 1,154 | |||||||||
Bare-metal stent systems | 19 | 24 | 47 | 62 | 66 | 86 | |||||||||||||||
Total coronary stent systems | $ | 458 | $ | 607 | $ | 572 | $ | 633 | $ | 1,030 | $ | 1,240 |
Q4 2012 Estimate | Full Year 2012 Estimate | ||||||||||||
(Low) | (High) | (Low) | (High) | ||||||||||
GAAP results | $ | 0.06 | $ | 0.09 | $ | (2.89 | ) | $ | (2.86 | ) | |||
Goodwill impairment charge | 3.09 | 3.09 | |||||||||||
Other intangible asset impairment charges | 0.09 | 0.09 | |||||||||||
Estimated acquisition-related net charges (credits) | 0.01 | 0.01 | (0.01 | ) | (0.01 | ) | |||||||
Estimated divestiture-related net credits | |||||||||||||
Estimated litigation-related charges | 0.05 | 0.05 | |||||||||||
Estimated restructuring-related charges (credits) | 0.02 | 0.02 | 0.07 | 0.07 | |||||||||
Estimated amortization expense | 0.06 | 0.06 | 0.23 | 0.23 | |||||||||
Estimated discrete tax items | |||||||||||||
Adjusted results | $ | 0.15 | $ | 0.18 | $ | 0.63 | $ | 0.66 | |||||
Goodwill and other intangible asset impairment charges - These amounts represent non-cash write-downs of the Company's goodwill balances attributable to its (a) U.S. Cardiac Rhythm Management reporting unit in the third quarter of 2012, (b) Europe/Middle East/Africa (EMEA) reporting unit recorded in the second quarter of 2012, and (c) U.S. Cardiac Rhythm Management reporting unit recorded in the first quarter of 2011 and non-cash write-downs of certain other intangible asset balances. Management removes the impact of non-cash impairment charges from the Company's operating performance to assist in assessing the Company's cash generated from operations. Management believes this is a critical metric for the Company in measuring the Company's ability to generate cash and invest in the Company's growth. Therefore, these charges are excluded from management's assessment of operating performance and are also excluded for purposes of calculating these non-GAAP financial measures to facilitate an evaluation of the Company's current operating performance and a comparison to the Company's past operating performance, particularly in terms of liquidity. |
Acquisition-related charges (credits) - These adjustments consist of (a) acquisition-related gains on previously held investments, (b) contingent consideration fair value adjustments, (c) due diligence, other fees and exit costs, and (d) inventory step-up adjustments. The acquisition-related gains on previously held investments are non-recurring benefits associated with acquisitions completed in the second quarter of 2012 and the first quarter of 2011. The contingent consideration adjustments represent accounting adjustments to state contingent consideration liabilities at their estimated fair value. These adjustments can be highly variable depending on the assessed likelihood and amount of future contingent consideration payments. Due diligence, other fees and exit costs include legal, tax, severance and other expenses associated with prior acquisitions that are not representative of on-going operations. The inventory step-up adjustment is a charge related to acquired inventory directly attributable to prior acquisitions and is not indicative of the Company's on-going operations, or on-going cost of products sold. Accordingly, management excluded these amounts for purposes of calculating these non-GAAP financial measures to facilitate an evaluation of the Company's current operating performance and a comparison to the Company's past operating performance. |
Divestiture-related charges (credits) - These amounts represent (a) gains resulting from business divestitures and (b) fees and separation costs associated with business divestitures. The Company completed the sale of its Neurovascular business in January 2011 and the resulting gains are not indicative of future operating performance and are not used by management to assess operating performance. Fees and separation costs represent those associated with the Company's divestiture of its Neurovascular business and are not representative of on-going operations. Accordingly, management excluded these amounts for purposes of calculating these non-GAAP financial measures to facilitate an evaluation of the Company's current operating performance and a comparison to the Company's past operating performance. |
Restructuring and restructuring-related costs - These adjustments represent primarily severance, costs to transfer production lines from one facility to another, and other direct costs associated with the Company's 2011 Restructuring plan, 2010 Restructuring plan and Plant Network Optimization program. These expenses are excluded by management in assessing the Company's operating performance, as well as from the Company's operating segments' measures of profit and loss used for making operating decisions and assessing performance. Accordingly, management excluded these charges for purposes of calculating these non-GAAP financial measures to facilitate an evaluation of the Company's current operating performance and a comparison to the Company's past operating performance. |
Litigation-related net charges - These adjustments include certain significant product liability and other litigation-related charges and credits. These amounts are excluded by management in assessing the Company's operating performance, as well as from the Company's operating segments' measures of profit and loss used for making operating decisions and assessing performance. Accordingly, management excluded these amounts for purposes of calculating these non-GAAP financial measures to facilitate an evaluation of the Company's current operating performance and a comparison to the Company's past operating performance. |
Discrete tax items - These items represent adjustments of certain tax positions, which were initially established in prior periods as a result of intangible asset impairment charges; acquisition-, divestiture-, restructuring- or litigation-related charges (credits). These adjustments do not reflect expected on-going operating results. Accordingly, management excluded these amounts for purposes of calculating these non-GAAP financial measures to facilitate an evaluation of the Company's current operating performance and a comparison to the Company's past operating performance. |
Amortization expense - Amortization expense is a non-cash charge and does not impact the Company's liquidity or compliance with the covenants included in its credit facility agreement. Management removes the impact of amortization from the Company's operating performance to assist in assessing the Company's cash generated from operations. Management believes this is a critical metric for the Company in measuring the Company's ability to generate cash and invest in the Company's growth. Therefore, amortization expense is excluded from management's assessment of operating performance and is also excluded from the measures management uses to set employee compensation. Accordingly, management has excluded amortization expense for purposes of calculating these non-GAAP financial measures to facilitate an evaluation of the Company's current operating performance, particularly in terms of liquidity. |
Changes in foreign currency exchange rates - The impact of changes in foreign currency exchange rates is highly variable and difficult to predict. Accordingly, management excludes the impact of changes in foreign currency exchange rates for purposes of reviewing regional and divisional revenue growth rates to facilitate an evaluation of the Company's current operating performance and a comparison to the Company's past operating performance. |
&%P+S$N,"\`/#]X<&%C:V5T(&)E9VEN/2?ON[\G
M(&ED/2=7-4TP37!#96AI2'IR95-Z3E1C>FMC.60G/SX*/'@Z>&UP;65T82!X
M;6QN K*+FK84,(I=J-2<*@^:U^=/]CHMOK(
M;C;E*D8J#\QP_P!GH\WR`Q0PV^4[-QRK@-K;JIDRF!F;PRT]7]Y$A5(H45?,
M\R2\Z1S;@6)]A39)3-:';Y.^>,T;U%/\'7MO8&V6V9PTT>#T8'XZ[_K-RL,3
MDJ2F7#Y3!3[9RLF0$T=-782:3Q"1Z4(YAEPDTQ>-V(M&Q`M>ZDF^V2V_ZB.?
M%5]:@<0PS^>KS^?1=NEN(U\5:^*&U"GKZ?F.FRJVMN+I+MM\MBZ(IMRFJ(L+
MN7.5L93!U.'R*1-CJ@4K.KY&+0X\@6\:H&1F`8^[BX@WC;/!D>LY&I5'Q!AQ
M%?+Y?D:=/1S17]H$<][+4`'((X_9\O/SZJI_F!?'3%=9;JGWGAZ6IDI:A!N+
M;GFJ%G\^WJV5H/X>DK!;2[5JXWHI`H4^***3G66]R+R1OS[C:K;3D>*G:U,=
MP''['%&^VH\NC2QF^K@5BWZJG2WVCS_VPH?S^75(/9&X H,F]NI;7F.QV[F/E
MUOK)V,46X6J!J`C/B_T*#.HX\O3I(9[='7/1FT\'B:JCR,6W\AD,KC:'%4-%
M_%ZZO?(&KRFX*RKI83`9*>=JR0R)"+MK*QJ2I]E*0WF[W5Q/&%$I-?05]!U)
MFY[GRI[3\NV7*US;SWMO=>)X@0`N0]3(Y6N`?(#.*])7K$X/8%'13=4YZ/-]
M-;IKPZX=,A)#D]DY.L<(7I8:G[>J^U)`1X)0"RJ+:9!ZS23;Y+]%26$Q;@BX
MK\+J/0^O47\K0M9WE-!Q7T/D?S_P`/0?YQY:W#VQYIM=PV^5DV
M:>;5:S>4,A-3`YX:6K1:X\O/HSS;7V;OK(8?.[PV7B:K>&Q,G%"D&2,]35[4
MSM(GFA6*6GJHJ7+XN6*05.-J)DFBFIG5EY!`+;D7VWE[-IF\#B/0@^8ZGGES
M:N2/<<6?,M_LT9Y@MG4RK4BDJ\&*@T<'B"1T#7S-W+O?$[4ZREVYN;.XG`YO
M?[[8FLW)EC_`*7A>*OV#HG6XMF?)?XI=Y9S
M=6YNBL[UYB=_Q-D
SC=[B4B:.SW>W=9T5J3.-,=15?#CD6I%1B20Z?X4(&KH17-S%8U7;]
MWCDNYE#'QV<11*PX1QNM'!XAW[?1//HHV[-Z87I>EWOOZ27I'O'-;^R,0S>V
M*O%=1=I]A[CAFDCFDEVFC8REWG@\;BZ>G)6!)J*C@5?$L\-[>[;)#O=Z+?;M
MT6!MA%5:=)77PG85#,T